Corvus Pharmaceuticals, Inc. – NASDAQ:CRVS
Founder-led company
Corvus Pharmaceuticals stock price today
$5.14
-0.07
-1.34%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in 3 days
Corvus Pharmaceuticals stock price monthly change
+154.15%
month
Corvus Pharmaceuticals stock price quarterly change
+154.15%
quarter
Corvus Pharmaceuticals stock price yearly change
+202.91%
year
Corvus Pharmaceuticals key metrics
Market Cap | 292.37M |
Enterprise value | 47.16M |
P/E | -1.28 |
EV/Sales | N/A |
EV/EBITDA | -0.83 |
Price/Sales | N/A |
Price/Book | 1.02 |
PEG ratio | -0.09 |
EPS | -0.52 |
Revenue | N/A |
EBITDA | -22.96M |
Income | -24.85M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeCorvus Pharmaceuticals stock price history
Corvus Pharmaceuticals stock forecast
Corvus Pharmaceuticals financial statements
Average Price Target
$12.5
Potential upside: 143.19%
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 0 | -6.50M | |
|---|---|---|---|
| Sep 2023 | 0 | -6M | |
| Dec 2023 | 246K | -6.65M | -2704.47% |
| Mar 2024 | 0 | -5.70M |
| Jun 2023 | 58041000 | 8.55M | 14.74% |
|---|---|---|---|
| Sep 2023 | 51942000 | 7.65M | 14.73% |
| Dec 2023 | 45553000 | 6.86M | 15.08% |
| Mar 2024 | 40084000 | 6.72M | 16.76% |
| Jun 2023 | -5.22M | -4.28M | 7.51M |
|---|---|---|---|
| Sep 2023 | -5.43M | 17.54M | 335K |
| Dec 2023 | -5.16M | -2.31M | 0 |
| Mar 2024 | -5.15M | -7K | 0 |
Corvus Pharmaceuticals alternative data
| Sep 2023 | 29 |
|---|---|
| Oct 2023 | 29 |
| Nov 2023 | 29 |
| Dec 2023 | 29 |
| Jan 2024 | 29 |
| Feb 2024 | 29 |
| Mar 2024 | 28 |
| Apr 2024 | 28 |
| May 2024 | 28 |
| Jun 2024 | 28 |
| Jul 2024 | 28 |
Corvus Pharmaceuticals other data
8.95%
-36.95%
of CRVS is owned by hedge funds
19
-21
4.16M
-17.20M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| May 2024 | 6859602 | 0 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Purchase | JONES WILLIAM BENTON officer: See Rema.. | Common Stock | 20,000 | $1.73 | $34,620 | ||
Purchase | JONES WILLIAM BENTON officer: See Rema.. | Warrant (Right to Buy) | 19,357 | $3.5 | $67,750 | ||
Purchase | MILLER RICHARD A MD director, officer.. | Common Stock | 577,634 | $1.73 | $999,884 | ||
Purchase | MILLER RICHARD A MD director, officer.. | Warrant (Right to Buy) | 559,073 | $3.5 | $1,956,756 | ||
Purchase | THOMPSON PETER A. director, 10 perc.. | Pre-Funded Warrants (right to buy) | 1,444,085 | N/A | N/A | ||
Purchase | THOMPSON PETER A. director, 10 perc.. | Common Warrants (right to buy) | 1,397,684 | $3.5 | $4,891,894 | ||
Purchase | ORBIMED ADVISORS LLC director, 10 percent owner: | Pre-Funded Warrants (right to buy) | 1,444,085 | N/A | N/A | ||
Purchase | ORBIMED ADVISORS LLC director, 10 percent owner: | Common Warrants (right to buy) | 1,397,684 | $3.5 | $4,891,894 | ||
Purchase | GRAIS LINDA director | Common Stock | 10,000 | $2.45 | $24,500 | ||
Purchase | JONES WILLIAM BENTON officer: See Rema.. | Common Stock | 20,000 | $0.79 | $15,800 |
| Patent |
|---|
Application Filling date: 5 Nov 2019 Issue date: 4 Aug 2022 |
Grant Utility: Pharmaceutical formulations Filling date: 1 Feb 2019 Issue date: 8 Mar 2022 |
Grant Filling date: 31 Aug 2018 Issue date: 22 Feb 2022 |
Application Filling date: 24 Sep 2020 Issue date: 19 Aug 2021 |
Application Filling date: 12 Jul 2019 Issue date: 19 Aug 2021 |
Application Filling date: 12 Jul 2019 Issue date: 19 Aug 2021 |
Application Filling date: 27 Aug 2020 Issue date: 22 Jul 2021 |
Grant Utility: Methods of treating cancer Filling date: 4 Apr 2018 Issue date: 22 Jun 2021 |
Application Filling date: 17 Dec 2020 Issue date: 27 May 2021 |
Grant Filling date: 3 Nov 2017 Issue date: 18 May 2021 |
| Quarter | Transcript |
|---|---|
| Q1 2024 6 May 2024 | Q1 2024 Earnings Call Transcript |
| Q4 2023 19 Mar 2024 | Q4 2023 Earnings Call Transcript |
| Q3 2023 7 Nov 2023 | Q3 2023 Earnings Call Transcript |
| Q2 2023 8 Aug 2023 | Q2 2023 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
| Mr. Leiv Lea (1954) Chief Financial Officer | $399,270 |
| Dr. William Benton Jones (1966) Senior Vice President of Pharmaceutical Devel. | $352,950 |
| Dr. Richard A. Miller M.D. (1951) Co-Founder, Pres, Chief Executive Officer & Chairman | $303,000 |
Dr. Peter A. Thompson FACP, M.D. (1960) Co-Founder & Independent Director | $47,000 |
Corvus Pharmaceuticals: Not Just A One-Hit Wonder In ITK Inhibitor Targeting
Corvus Pharmaceuticals Is Ready To Take Flight
Corvus Pharmaceuticals: Ahead Of The Clinical-Stage Curve
Corvus Pharmaceuticals: Targeting $1 Billion/Year U.S. T-Cell Lymphoma Market
Week In Review: Fosun Pharma Acquires Majority Stake In China Vaccine Company For $682 Million
Corvus Pharmaceuticals: More Than A CD73 Sympathy Play
SA Marketplace 2021 Top Idea Contest: Mid-Year Update
-
What's the price of Corvus Pharmaceuticals stock today?
One share of Corvus Pharmaceuticals stock can currently be purchased for approximately $5.14.
-
When is Corvus Pharmaceuticals's next earnings date?
Unfortunately, Corvus Pharmaceuticals's (CRVS) next earnings date is currently unknown.
-
Does Corvus Pharmaceuticals pay dividends?
No, Corvus Pharmaceuticals does not pay dividends.
-
How much money does Corvus Pharmaceuticals make?
Corvus Pharmaceuticals has a market capitalization of 292.37M.
-
What is Corvus Pharmaceuticals's stock symbol?
Corvus Pharmaceuticals, Inc. is traded on the NASDAQ under the ticker symbol "CRVS".
-
What is Corvus Pharmaceuticals's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Corvus Pharmaceuticals?
Shares of Corvus Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Corvus Pharmaceuticals's key executives?
Corvus Pharmaceuticals's management team includes the following people:
- Mr. Leiv Lea Chief Financial Officer(age: 71, pay: $399,270)
- Dr. William Benton Jones Senior Vice President of Pharmaceutical Devel.(age: 59, pay: $352,950)
- Dr. Richard A. Miller M.D. Co-Founder, Pres, Chief Executive Officer & Chairman(age: 74, pay: $303,000)
- Dr. Peter A. Thompson FACP, M.D. Co-Founder & Independent Director(age: 65, pay: $47,000)
-
Is Corvus Pharmaceuticals founder-led company?
Yes, Corvus Pharmaceuticals is a company led by its founders Dr. Richard A. Miller M.D. and Dr. Peter A. Thompson FACP, M.D..
-
How many employees does Corvus Pharmaceuticals have?
As Jul 2024, Corvus Pharmaceuticals employs 28 workers.
-
When Corvus Pharmaceuticals went public?
Corvus Pharmaceuticals, Inc. is publicly traded company for more then 9 years since IPO on 23 Mar 2016.
-
What is Corvus Pharmaceuticals's official website?
The official website for Corvus Pharmaceuticals is corvuspharma.com.
-
Where are Corvus Pharmaceuticals's headquarters?
Corvus Pharmaceuticals is headquartered at 863 Mitten Road, Burlingame, CA.
-
How can i contact Corvus Pharmaceuticals?
Corvus Pharmaceuticals's mailing address is 863 Mitten Road, Burlingame, CA and company can be reached via phone at +65 09004520.
-
What is Corvus Pharmaceuticals stock forecast & price target?
Based on 2 Wall Street analysts` predicted price targets for Corvus Pharmaceuticals in the last 12 months, the avarage price target is $12.5. The average price target represents a 143.19% change from the last price of $5.14.
Corvus Pharmaceuticals company profile:
Corvus Pharmaceuticals, Inc.
corvuspharma.comExchange:
NASDAQ
Full time employees:
28
Industry:
Biotechnology
Sector:
Healthcare
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The company also develops CPI-818, a covalent inhibitor of ITK, which is in Phase I/Ib clinical trial to treat patients with various malignant T-cell lymphomas, as well as designed to inhibit the proliferation of certain malignant T-cells; and Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor that is in Phase II clinical trial for patients with either advanced or refractory renal cell cancer. Its preclinical stage products include CPI-182, an antibody designed to block inflammation and myeloid suppression; and CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a strategic collaboration with Angel Pharmaceuticals for the development its pipeline of targeted investigational medicines. The company was incorporated in 2014 and is based in Burlingame, California.
863 Mitten Road
Burlingame, CA 94010
Burlingame, CA 94010
CIK: 0001626971
ISIN: US2210151005
CUSIP: 221015100
